What is the optimal anticoagulation level with argatroban during percutaneous coronary intervention?
Ignacio Cruz‐González(Instituto de Investigación Biomédica de Salamanca), Ik‐Kyung Jang(Massachusetts General Hospital), Hikari Watanabe(Mitsubishi Group (Japan)), Josephine L. Healy(Harvard University), Suzanne J. Baron(Harvard University), Masanori Osakabe(Mitsubishi Group (Japan)), Robert W. Yeh(Beth Israel Deaconess Medical Center), María Sánchez Ledesma(Complejo Hospitalario de Salamanca)
Cited by 9
Related Papers
From Vulnerable Plaque to Vulnerable Patient
|Circulation|2003|2.7k
From Vulnerable Plaque to Vulnerable Patient
|Circulation|2003|2.3k
In Vivo Diagnosis of Plaque Erosion and Calcified Nodule in Patients With Acute Coronary Syndrome by Intravascular Optical Coherence Tomography
|Journal of the American College of Cardiology|2013|840
Clinical outcomes of state-of-the-art percutaneous coronary revascularization in patients with de novo three vessel disease: 1-year results of the SYNTAX II study
|European Heart Journal|2017|295
Evaluating Real-World Clinical Outcomes in Atrial Fibrillation Patients Receiving the WATCHMAN Left Atrial Appendage Closure Technology
|Circulation Arrhythmia and Electrophysiology|2019|286